Impact of Covid-19 in Congenital Heart Disease - COVID-CHD
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,000
- 试验地点
- 1
- 主要终点
- Prevalence of Covid-19 infection in the overall CHD population
研究概览
简要总结
The ongoing Coronavirus (Covid-19) pandemic has recently generated the first epidemiological data on populations at risk. Currently, the risk factors, recognized for severe forms of Covid-19 infection, are elderly patients (> 70 years), obese patients, patients with chronic renal or respiratory diseases, cardiovascular history (stroke or coronary artery disease), high blood pressure, diabetes, and cancer.
The population of congenital heart disease (CHD) might also be at risk, however, no data is available in this group of patients.
CHD is the leading cause of birth defects, and as a result of recent medical advances, currently the number of adults with CHD exceeds the number of children, with an increasing prevalence of complex CHD. Approximately 200,000 children and 250,000 adults are living with a CHD in France today.
The French Society of Cardiology, coordinator of this study, issued recommendations on March 14, 2020 for the French CHD population on the basis of expert opinions based essentially on the data published in the general population. Nevertheless, there is a need to provide scientific data on the impact of Covid-19 in the pediatric and adult CHD population.
This study aims to assess the morbidity, the mortality and the risk factors associated with Covid-19 in patients with CHD in France
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Prevalence of Covid-19 infection in the overall CHD population
时间窗: through study completion, an average of 2 weeks
Prevalence of Covid-19 infection in the overall CHD population
次要结局
- Cardiovascular complications(through study completion, an average of 2 weeks)
- Other complications(through study completion, an average of 2 weeks)
- Number of deaths(through study completion, an average of 2 weeks)
- Prevalence of Covid-19 infection per CHD sub-group(through study completion, an average of 2 weeks)